Xilio Q2 Revenue Jumps 131% to $18.7M, FDA Clears XTX501 IND
XLO sits 42% above its 52-week low of $6.465 on light trading volume (0.2× avg).
Summary
Xilio reported Q2 revenue of $18.7M, up 131% year-over-year, with a net loss of $6.4M. The FDA cleared the IND for XTX501, a bispecific PD-1/masked IL-2, with Phase 1 dosing in metastatic NSCLC and select solid tumors starting H2 2026 and initial data expected H2 2027. This follows the 8-K and 10-Q filed August 12, which disclosed the cash position and runway extension into early 2028. The revenue surge and clinical milestone are material for a $60M market cap company, though the stock fell 4.2% for the quarter. Watch for Phase 1 dosing initiation and any updates on the ATM program.
At the time of this announcement, XLO was trading at $9.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $60.3M. The 52-week trading range was $6.47 to $12.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.